The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. The updated ...

Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions on an innovative clinical trials program designed to match patients with acute myeloid leukemia (AML) and ...

– Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – NPM1 mutations are among the most common founder mutations in AML, occurring in ...

Caribou plans a pivotal Phase 3 randomized trial evaluating approximately 250 patients in second-line large B-cell lymphoma. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy, Orphan ...

This model illustrates how SETD1B promotes the expansion of H3K4me3 epigenetic marks and upregulates MYC expression, driving cytokine-independent cell growth in FLT3-mutated AML. Acute myeloid ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid leukemia (AML), which is associated with an increased risk of relapse. The ...

SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on ...